Fundraising Fox
/Investor DB
Sign in

AMR Action Fund — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

VENATORX PHARMACEUTICALS INCvenatorx.comSeries C · Mar 2022 · $34M

Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.

BiotechMalvern, US

Christopher J. Burns(Executive Officer, Director)Daniel C. Pevear(Executive Officer)Michael Diem(Director)Vincent J. Milano(Director)Ezra Felker(Executive Officer)Shelley Chu(Director)

Board seatMartin Heidecker· per SEC Form D

Co-investorsBioAdvanceForesite CapitalVersant Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.